ORLANDO, FL, USA (UroToday.com) - The most common site of metastases in CRPC is to the bone, and other sites that are less common include lymph nodes, liver, lung, and soft tissue. Of all men with metastatic CRPC (mCRPC), about 90% have bone disease. The theory for this study was that with new therapies for mCRPC that extends survival in men with mCRPC, plus the new bone-targeted treatments, the incidence of non-bone metastases would increase with time.